Rennie L Rhee1, Nicole B Gabler2, Sapna Sangani1, Amy Praestgaard2, Peter A Merkel1,2, Steven M Kawut2,3. 1. 1 Division of Rheumatology. 2. 2 Center for Clinical Epidemiology and Biostatistics, and. 3. 3 Pulmonary, Allergy, and Critical Care Division, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.
Abstract
RATIONALE: Studies suggest that patients with connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) have a poorer treatment response to therapies for PAH compared with patients with idiopathic PAH (IPAH), but individual randomized controlled trials (RCTs) have been underpowered to examine differences within these subgroups. OBJECTIVES: To compare the effect of therapy for PAH in CTD-PAH versus IPAH. METHODS: We obtained individual participant data from phase III placebo-controlled RCTs of therapies for PAH submitted to the U.S. Food and Drug Administration for drug approval. A treatment-by-diagnosis interaction term evaluated differences in treatment response between CTD-PAH and IPAH. Outcomes included change in 6-minute-walk distance (∆6MWD) from baseline to 12 weeks, clinical worsening, and all-cause mortality. MEASUREMENTS AND MAIN RESULTS: The study sample included 827 participants with CTD-PAH and 1,935 with IPAH from 11 RCTs. Patients with CTD-PAH had less improvement in 6MWD when assigned to active treatment versus placebo compared with patients with IPAH (difference in treatment effect on ∆6MWD in CTD-PAH vs. IPAH, -17.3 m; 90% confidence interval, -31.3 to -3.3; P for interaction = 0.043). Treatment was less effective in reducing the occurrence of clinical worsening in CTD-PAH versus IPAH (P for interaction = 0.012), but there was no difference in the placebo-adjusted effect of treatment on mortality (P for interaction = 0.65). CONCLUSIONS: Treatment for PAH was less effective in CTD-PAH compared with IPAH in terms of increasing 6MWD and preventing clinical worsening. The heterogeneity of treatment response supports the need for identifying therapies that are more effective for CTD-PAH.
RCT Entities:
RATIONALE: Studies suggest that patients with connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) have a poorer treatment response to therapies for PAH compared with patients with idiopathic PAH (IPAH), but individual randomized controlled trials (RCTs) have been underpowered to examine differences within these subgroups. OBJECTIVES: To compare the effect of therapy for PAH in CTD-PAH versus IPAH. METHODS: We obtained individual participant data from phase III placebo-controlled RCTs of therapies for PAH submitted to the U.S. Food and Drug Administration for drug approval. A treatment-by-diagnosis interaction term evaluated differences in treatment response between CTD-PAH and IPAH. Outcomes included change in 6-minute-walk distance (∆6MWD) from baseline to 12 weeks, clinical worsening, and all-cause mortality. MEASUREMENTS AND MAIN RESULTS: The study sample included 827 participants with CTD-PAH and 1,935 with IPAH from 11 RCTs. Patients with CTD-PAH had less improvement in 6MWD when assigned to active treatment versus placebo compared with patients with IPAH (difference in treatment effect on ∆6MWD in CTD-PAH vs. IPAH, -17.3 m; 90% confidence interval, -31.3 to -3.3; P for interaction = 0.043). Treatment was less effective in reducing the occurrence of clinical worsening in CTD-PAH versus IPAH (P for interaction = 0.012), but there was no difference in the placebo-adjusted effect of treatment on mortality (P for interaction = 0.65). CONCLUSIONS: Treatment for PAH was less effective in CTD-PAH compared with IPAH in terms of increasing 6MWD and preventing clinical worsening. The heterogeneity of treatment response supports the need for identifying therapies that are more effective for CTD-PAH.
Authors: Paola Coral-Alvarado; Adriana Rojas-Villarraga; María C Latorre; Ruben D Mantilla; José F Restrepo; Aryce L Pardo; Philippe Chalem; Federico Rondón; Edwin Jáuregui; Juan C Rueda; Carlos Cañas; María E Hincapie; Ricardo Pineda-Tamayo; Fausto Alvarez; Antonio Iglesias-Gamarra; Francisco J Diaz; Juan-Manuel Anaya Journal: J Rheumatol Date: 2008-01-15 Impact factor: 4.666
Authors: Nazzareno Galiè; Hossein A Ghofrani; Adam Torbicki; Robyn J Barst; Lewis J Rubin; David Badesch; Thomas Fleming; Tamiza Parpia; Gary Burgess; Angelo Branzi; Friedrich Grimminger; Marcin Kurzyna; Gérald Simonneau Journal: N Engl J Med Date: 2005-11-17 Impact factor: 91.245
Authors: Vallerie V McLaughlin; Raymond L Benza; Lewis J Rubin; Richard N Channick; Robert Voswinckel; Victor F Tapson; Ivan M Robbins; Horst Olschewski; Melvyn Rubenfire; Werner Seeger Journal: J Am Coll Cardiol Date: 2010-05-04 Impact factor: 24.094
Authors: Hossein-Ardeschir Ghofrani; Nazzareno Galiè; Friedrich Grimminger; Ekkehard Grünig; Marc Humbert; Zhi-Cheng Jing; Anne M Keogh; David Langleben; Michael Ochan Kilama; Arno Fritsch; Dieter Neuser; Lewis J Rubin Journal: N Engl J Med Date: 2013-07-25 Impact factor: 91.245
Authors: David B Badesch; Nicholas S Hill; Gary Burgess; Lewis J Rubin; Robyn J Barst; Nazzareno Galiè; Gerald Simonneau Journal: J Rheumatol Date: 2007-11-01 Impact factor: 4.666
Authors: Nazzareno Galiè; Marius M Hoeper; Marc Humbert; Adam Torbicki; Jean-Luc Vachiery; Joan Albert Barbera; Maurice Beghetti; Paul Corris; Sean Gaine; J Simon Gibbs; Miguel Angel Gomez-Sanchez; Guillaume Jondeau; Walter Klepetko; Christian Opitz; Andrew Peacock; Lewis Rubin; Michael Zellweger; Gerald Simonneau Journal: Eur Heart J Date: 2009-08-27 Impact factor: 29.983
Authors: Valentina Mercurio; Monica Mukherjee; Ryan J Tedford; Roham T Zamanian; Rubina M Khair; Takahiro Sato; Omar A Minai; Fernando Torres; Reda E Girgis; Kelly Chin; Rachel Damico; Todd M Kolb; Stephen C Mathai; Paul M Hassoun Journal: Am J Respir Crit Care Med Date: 2018-02-01 Impact factor: 21.405
Authors: John H Newman; Stuart Rich; Steven H Abman; John H Alexander; John Barnard; Gerald J Beck; Raymond L Benza; Todd M Bull; Stephen Y Chan; Hyung J Chun; Declan Doogan; Jocelyn Dupuis; Serpil C Erzurum; Robert P Frantz; Mark Geraci; Hunter Gillies; Mark Gladwin; Michael P Gray; Anna R Hemnes; Roy S Herbst; Adrian F Hernandez; Nicholas S Hill; Evelyn M Horn; Kendall Hunter; Zhi-Cheng Jing; Roger Johns; Sanjay Kaul; Steven M Kawut; Tim Lahm; Jane A Leopold; Greg D Lewis; Stephen C Mathai; Vallerie V McLaughlin; Evangelos D Michelakis; Steven D Nathan; William Nichols; Grier Page; Marlene Rabinovitch; Jonathan Rich; Franz Rischard; Sharon Rounds; Sanjiv J Shah; Victor F Tapson; Naomi Lowy; Norman Stockbridge; Gail Weinmann; Lei Xiao Journal: Am J Respir Crit Care Med Date: 2017-06-15 Impact factor: 21.405
Authors: Rahul G Argula; Abhijit Karwa; Abigail Lauer; David Gregg; Richard M Silver; Carol Feghali-Bostwick; Lynn M Schanpp; Kim Egbert; Bruce W Usher; Viswanathan Ramakrishnan; Paul M Hassoun; Charlie Strange Journal: Ann Am Thorac Soc Date: 2017-05